New partnership expands patient access to cancer clinical trials

New partnership expands patient access to cancer clinical trials

The University of Chicago Medicine Comprehensive Cancer Center (UCCCC) and Eli Lilly and Company (Lilly) have partnered to help patients gain greater access to potential cancer treatments by participating in clinical trials.

Corpus Christi Medical Center expands radiation cancer treatment capabilities

Cancer treatment has taken a giant leap forward in the Coastal Bend.The ribbon cutting marks the end of construction of a new radiation therapy facility and upgrades to the center's cancer fighting technology.Ashley Janek, director of Corpus Christi Medical Center, said the new machines offer significant advances in precision and real-time imaging."The machines are incredible. They provide pinpoint precision, real-time tumor localization, accura…

Clinical Trials Round-Up: May and June 2026

May and June delivered a plethora of clinical trial updates. In the build-up to ASCO in June, our inbox was overflowing with oncology trial results.

New Dana-Farber center expands cancer care at Sturdy Health – North Star Reporter

By Geena Monahan—For the North Star Reporter Cancer patients in the Attleboro area can now receive Dana-Farber Cancer Institute treatment closer to home, following the opening of a new outpatient center at Sturdy Health. Dana-Farber and Sturdy Health officially opened the clinic Thursday, Aug. 6, on the third floor of Sturdy’s Cancer & Specialty Care […]

How Is City of Hope Widening National Clinical Trial Access for Oncology?

City of Hope’s national clinical trials model can activate a study across a network of 40 sites in 4 states within 90 days, according to Edward Kim, MD, MBA.

UChicago Medicine Cancer Center and Lilly Partner to Expand Clinical Trial

The University of Chicago Medicine Comprehensive Cancer Center and Eli Lilly and Company have launched a two-year partnership aimed at expanding patient access to cancer clinical trials, including studies testing investigational therapies that are not yet available through routine medical care. The collaboration is designed to move beyond the traditional sponsor-site model, in which pharmaceutical companies and medical centers typically coordina…